Physician profile
Timothy W Smith
NPI 1972680627
$104,379.85
in general payments reported to CMS, 2019-2025
47 companies · $5,491 in 2025
The $5,491 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $31K · 2021: $8,347 · 2022: $14K · 2023: $6,191 · 2024: $5,805 · 2025: $5,491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $5,576 · Travel and Lodging: $128 · Education: $68.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,713.51 |
| Food and Beverage | $5,575.92 |
| Travel and Lodging | $128.46 |
| Education | $68.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $32,695.84 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Mylan Specialty L.P. | $28,497.78 | 2019-2024 | Yupelri, Yupelri |
| Astrazeneca Pharmaceuticals LP | $20,471.45 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Regeneron Healthcare Solutions, INC. | $7,183.69 | 2019-2025 | Dupixent |
| Genzyme Corporation | $3,130.89 | 2019-2025 | |
| Viatris Specialty LLC | $2,222.03 | 2025 | Yupelri |
| Medtronic Vascular, INC. | $2,104.24 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,552.97 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Verona Pharma, INC. | $1,532.41 | 2025 | Ohtuvayre |
| Jazz Pharmaceuticals INC. | $457.68 | 2019-2025 | Xywav |
| Sunovion Pharmaceuticals INC. | $420.18 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $410.46 | 2021-2025 | Opsumit, Uptravi |
| Genentech USA, INC. | $347.07 | 2019-2024 | Xolair |
| Insmed, INC. | $322.80 | 2019-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $311.82 | 2019-2024 | Prolastin-C Liquid |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $254.51 | 2022-2025 | Tezspire, Prolia, Evenity |
| Teva Pharmaceuticals USA, INC. | $244.92 | 2019-2022 | |
| United Therapeutics Corporation | $239.35 | 2023-2025 | Tyvaso |
| Novartis Pharmaceuticals Corporation | $221.03 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $190.47 | 2019-2023 | Belsomra, Verquvo, Dificid |
| Mallinckrodt Hospital Products INC. | $181.84 | 2022-2023 | Acthar |
| Abbvie INC. | $158.97 | 2021-2024 | Avycaz, Teflaro |
| Philips North America LLC | $155.24 | 2019-2025 | (8874) Incourage, Encore |
| Eisai INC. | $129.31 | 2020-2021 | |
| Lilly USA, LLC | $104.66 | 2023-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.94 | 2023-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $102.25 | 2020-2023 | Glassia |
| Inogen, INC. | $64.41 | 2022-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Janssen Pharmaceuticals, INC | $63.16 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $59.80 | 2025 | |
| Advanced Respiratory, INC | $58.24 | 2019-2020 | |
| Allergan, INC. | $50.14 | 2019-2020 | |
| Electromed, INC. | $45.36 | 2019-2023 | Smartvest |
| Nabriva Therapeutics, Plc | $44.84 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $37.08 | 2025 | Purified Cortrophin Gel |
| Axsome Therapeutics, INC. | $26.64 | 2023 | Sunosi |
| Shire North American Group INC | $23.68 | 2019 | |
| Baxter Healthcare | $22.49 | 2025 | Hillrom - Vest System Model 205 Acute Care |
| Pfizer INC. | $21.53 | 2025 | |
| Alnylam Pharmaceuticals INC. | $18.58 | 2024 | Amvuttra |
| Novo Nordisk INC | $18.27 | 2024 | Wegovy |
| Idorsia Pharmaceuticals US INC | $14.88 | 2023 | Quviviq |
| Ibsa Pharma INC. | $14.10 | 2024 | Tirosint, Licart |
| Horizon Therapeutics Plc | $13.98 | 2020 | |
| Phadia US INC. | $13.54 | 2021 | |
| Circassia INC. | $11.23 | 2019 | |
| Phathom Pharmaceuticals, INC. | $11.10 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.